Comparison of goserelin and leuprolide in combined androgen blockade therapy

Urology

Volumn 52, Issue 1, 1998, Pages 82-88

  Sarosdy, Michael F ^a   Schellhammer, Paul F ^a   Sharifi, Roohollah ^a   Block, Norman L ^a   Soloway, Mark S ^a   Venner, Peter M ^a   Patterson, A Lynn ^a   Vogelzang, Nicholas J ^a   Chodak, Gerald W ^a   Klein, Eric A ^a   Schellenger, Julie Jones ^a   Kolvenbag, Geert J C M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FACTORIAL ANALYSIS; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FLUTAMIDE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0032126847     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00145-9     Document Type: Article

References (20)

1. 1. Kirby RS: Recent advances in the medical management of prostate cancer. Br J Clin Prac 50: 88-93, 1996.
2. 2. Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 1281-1286, 1984.
3. 3. Waymont B, Lynch TH, Dunn JA, et al: Phase III randomized study of Zoladex versus stilbestrol in the treatment of advanced prostate cancer. Br J Urol 69: 614-620, 1992.
4. 4. Cassileth BR, Soloway MS, Vogelzang NJ, et al: Patient's choice of treatment in stage D prostate cancer. Urology 33(Suppl): 57-62, 1989.
5. 5. Cassileth BR, Soloway MS, Vogelzang NJ, et al: Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1: 322-329, 1992.
6. 6. Taub M, Begas A, and Love N: Advanced prostate cancer. Postgrad Med 100: 139-154, 1996.
7. 7. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med 321: 419-424, 1989.
8. 8. Janknegt RA, for the Anandron International Study Group: Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Cancer 72(Suppl): 3874-3877, 1993.
9. 9. Dijkman GA, Debruyne FMJ, and Janknegt RA: Long-term efficacy and safety of nilutamide plus orchidectomy in advanced prostate cancer, and the significance of early prostatic specific antigen normalization. J Urol 155(suppl): 609A, 1996.
10. 10. Denis LJ, Carneiro de Moura JL, Bono A, et al: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119-130, 1993.
11. 2 adenocarcinoma of the prostate (CaP): results of NCI Intergroup study 0105 (SWOG and ECOG). J Urol 157(Suppl): 336, 1997.
12. 12. Schellhammer P, Sharifi R, Block N, et al, for the Casodex Combination Study Group: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-752, 1995.
13. 13. Schellhammer P, Sharifi R, Block N, et al, for the Casodex Combination Study Group: Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 47(Suppl 1A): 54-60, 1996.
14. 14. Schellhammer PF, Sharifi R, Block NL, et al, for the Casodex Combination Study Group: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone releasing hormone analogue therapy, in patients with advanced prostate cancer: analysis of time to progression. Cancer 78: 2164-2169, 1996.
15. 15. Schellhammer P, Sharifi R, Block N, et al, for the Casodex Combination Study Group: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 50: 330-336, 1997.
16. 16. Kaisary AV, Tyrrell CJ, Peeling WB, et al: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67: 502-508, 1991.
17. 17. Vogelzang NJ, Chodak GW, Soloway MS, et al, for the Zoladex Prostate Study Group: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 46: 220-226, 1995.
18. 18. Klotz L: The Crawford et al article reviewed. Oncology 11: 1163-1165, 1997.
19. 19. Fenton MA, Shuster TD, Fertig AM, et al: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3: 1383-1388, 1997.
20. 20. Schellhammer PF, Venner P, Haas GP, et al: Prostate-specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157: 1731-1735, 1997.